Anti-inflammatory functions of apolipoprotein A-I and high-density lipoprotein are preserved in trimeric apolipoprotein A-I

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 1, 2013, Pages 41-49

  Murphy, Andrew J ^a   Hoang, Anh ^a   Aprico, Andrea ^a   Sviridov, Dmitri ^a   Chin Dusting, Jaye ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; CD11B ANTIGEN; HIGH DENSITY LIPOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; RECOMBINANT PROTEIN; TRIMERIC APOLIPOPROTEIN A1; TRIMERIC HIGH DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; ENDOTHELIUM; HEART PROTECTION; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; MONOCYTE; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHEAR FLOW;

EID: 84871690038     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.199257     Document Type: Article

References (31)

1. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, and Weintraub W; AIM-HIGH Investigators (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365:2255-2267.
2. Diamond MS, Staunton DE, Marlin SD, and Springer TA (1991) Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation. Cell 65:961-971. (Pubitemid 121001684)
3. Drew BG, Duffy SJ, and Formosa MF, et al. (2009) High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119: 2103-2111.
4. Favari E, Calabresi L, Adorni MP, Jessup W, Simonelli S, Franceschini G, and Bernini F (2009) Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry 48:11067-11074.
5. Gordon T, Castelli WP, Hjortland MC, Kannel WB, and Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62:707-714. (Pubitemid 8110784)
6. Graversen JH, Laurberg JM, Andersen MH, Falk E, Nieland J, Christensen J, Etzerodt M, Thøgersen HC, and Moestrup SK (2008) Trimerization of apolipoprotein A-I retards plasma clearance and preserves antiatherosclerotic properties. J Cardiovasc Pharmacol 51:170-177. (Pubitemid 351301478)
7. Gresham HD, Goodwin JL, Allen PM, Anderson DC, and Brown EJ (1989) A novel member of the integrin receptor family mediates Arg-Gly-Asp-stimulated neutrophil phagocytosis. J Cell Biol 108:1935-1943. (Pubitemid 19130526)
8. Hoang A, Drew BG, Low H, Remaley AT, Nestel P, Kingwell BA, and Sviridov D (2012) Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein. Eur Heart J 33:657-665.
9. Kimura T, Tomura H, andMogi C, et al. (2006) Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J Biol Chem 281:37457-37467. (Pubitemid 46042049)
10. Lorenzi I, von Eckardstein A, Radosavljevic S, and Rohrer L (2008) Lipidation of apolipoprotein A-I by ATP-binding cassette transporter (ABC) A1 generates an interaction partner for ABCG1 but not for scavenger receptor BI. Biochim Biophys Acta 1781: 306-313.
11. McGrath KC, Li XH, Puranik R, Liong EC, Tan JT, Dy VM, DiBartolo BA, Barter PJ, Rye KA, and Heather AK (2009) Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 29:877-882.
12. Murphy AJ, Akhtari M, and Tolani S, et al. (2011a) ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest 121:4138-4149.
13. Murphy AJ, Chin-Dusting J, and Sviridov D (2009a) Reconstituted HDL: a therapy for atherosclerosis and beyond. Clin Lipid 4:731-739.
14. Murphy AJ, Chin-Dusting JP, Sviridov D, and Woollard KJ (2009b) The anti inflammatory effects of high density lipoproteins. Curr Med Chem 16:667-675.
15. Murphy AJ, Remaley AT, and Sviridov D (2010) HDL therapy: two kinds of right? Curr Pharm Des 16:4134-4147.
16. Murphy AJ, Sviridov D, and Chin-Dusting JP (2006) Lipids and the endothelium: an update. Future Lipidol 1:517-526.
17. Murphy AJ, Westerterp M, Yvan-Charvet L, and Tall AR (2012) Anti-atherogenic mechanisms of high density lipoprotein: effects on myeloid cells. Biochim Biophys Acta 1821: 513-521.
18. Murphy AJ and Woollard KJ (2010) High-density lipoprotein: a potent inhibitor of inflammation. Clin Exp Pharmacol Physiol 37:710-718.
19. Murphy AJ, Woollard KJ, Hoang A, Mukhamedova N, Stirzaker RA, McCormick SP, Remaley AT, Sviridov D, and Chin-Dusting J (2008) High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 28:2071-2077.
20. Murphy AJ, Woollard KJ, Suhartoyo A, Stirzaker RA, Shaw J, Sviridov D, and Chin- Dusting JP (2011b) Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein A-I in in vitro and in vivo models of inflammation. Arterioscler Thromb Vasc Biol 31:1333-1341.
21. Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Crowe T, Kapadia S, and Nissen SE (2006) Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol 47: 992-997.
22. Nissen SE, Tsunoda T, and Tuzcu EM, et al. (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290:2292-2300. (Pubitemid 37430562)
23. Ohnsorg PM, Mary JL, Rohrer L, Pech M, Fingerle J, and von Eckardstein A (2011) Trimerized apolipoprotein A-I (TripA) forms lipoproteins, activates lecithin: cholesterol acyltransferase, elicits lipid efflux, and is transported through aortic endothelial cells. Biochim Biophys Acta 1811:1115-1123.
24. Patel S, Drew BG, and Nakhla S, et al. (2009) Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol 53: 962-971.
25. Pedersen TX, Bro S, Andersen MH, Etzerodt M, Jauhiainen M, Moestrup S, and Nielsen LB (2009) Effect of treatment with human apolipoprotein A-I on atherosclerosis in uremic apolipoprotein-E deficient mice. Atherosclerosis 202: 372-381.
26. Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger- Maddux R and Mathieson J (2009) Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 158:896-901 e3.
27. Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P, Mukhamedova N, Woollard K, Lyon S, Sviridov D, and Dart AM (2008) Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res 103: 1084-1091.
28. Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:301-314.
29. Sviridov D, Hoang A, Sawyer WH, and Fidge NH (2000) Identification of a sequence of apolipoprotein A-I associated with the activation of Lecithin:Cholesterol acyltransferase. J Biol Chem 275:19707-19712. (Pubitemid 30441567)
30. Tardif JC, Grégoire J, and L'Allier PL, et al.; Effect of rHDL on Atherosclerosis- Safety and Efficacy (ERASE) Investigators (2007) Effects of reconstituted highdensity lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297:1675-1682.
31. Westerterp M, Gourion-Arsiquaud S, Murphy AJ, Shih A, Cremers S, Levine RL, Tall AR, and Yvan-Charvet L (2012) Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell 11:195-206.